Osteogenesis imperfecta - Clinical and molecular diversity

European Cells and Materials

Volumn 5, Issue , 2003, Pages 41-47

  Roughley, P J ^a   Rauch, F ^a   Glorieux, F H ^a   Hofstetter, W ^b   Alini, M ^b  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^b NONE

Author keywords

Bisphosphonate therapy; Bone; Classification; Gene mutation; Osteogenesis imperfecta; Type I collagen

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; PAMIDRONIC ACID;

ARTICLE; BONE MASS; BONE STRUCTURE; CLINICAL FEATURE; DISEASE CLASSIFICATION; EXON; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; OSTEOGENESIS IMPERFECTA; PATHOLOGIC FRACTURE; TRIPLE HELIX; CLASSIFICATION; GENETICS; REVIEW;

HUMANS; MUTATION, MISSENSE; OSTEOGENESIS IMPERFECTA; VARIATION (GENETICS);

EID: 3242683387     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v005a04     Document Type: Article

References (34)

1. Aitchison K, Ogilvie D, Honeyman M, Thompson E, Sykes B (1988) Homozygous osteogenesis imperfecta unlinked to collagen I genes. Hum Genet 78: 233-236.
2. Bateman JF, Lamande SR, Hannagan M, Moeller I, Dahl HHM, Cole WG (1993) Chemical cleavage method for the detection of RNA base changes: experience in the application to collagen mutations in osteogenesis imperfecta. Amer J Med Genet 45: 233-240.
3. Burr DB (2002) Targeted and nontargeted remodeling. Bone 30: 2-4.
4. Byers PH (2000) Osteogenesis imperfecta: perspectives and opportunities. Curr Opin Pediatr 12: 603-609.
5. Byers PH, Steiner RD (1992) Osteogenesis imperfecta. Annu Rev Med 43: 269-282.
6. Cinman N (2001) Osteogenesis imperfecta. A life not so fragile. Lancet 358 Suppl: S46.
7. Dalgleish R (1997) The human type I collagen mutation database. Nucleic Acids Res 25: 181-187.
8. Engelbert RH, Pruijs HE, Beemer FA, Helders PJ (1998) Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil 79: 1590-1594.
9. Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19: 80-100.
10. Forlino A, Marini JC (2000) Osteogenesis imperfecta: prospects for molecular therapeutics. Mol Genet Metab 71: 225-232.
11. Ganguly A, Rock MJ, Prockop DJ (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci 90: 10325-10329.
12. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947-952.
13. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ (2000) Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 15: 1650-1658.
14. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17: 30-38.
15. Kocher MS, Shapiro F (1998) Osteogenesis imperfecta. J Am Acad Orthop Surg 6: 225-236.
16. Korkko J, Ala-Kokko L, De Paepe A, Nuytinck L, Earley J, Prockop DJ (1998) Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations. Am J Hum Genet 62: 98-110.
17. Labuda M, Morissette J, Ward LM, Rauch F, Lalic L, Roughley PJ, Glorieux FH (2002) Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 31: 19-25.
18. Niyibizi C, Wallach CJ, Mi Z, Robbins PD (2002) Approaches for skeletal gene therapy. Crit Rev Eukaryot Gene Expr 12: 163-173.
19. Nollau P, Wagener C (1997) Methods for detection of point mutations: performance and quality assessment. Clin Chem 43: 1114-1128.
20. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF (1996) A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11: 150-159.
21. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85: 1846-1850.
22. Primorac D, Rowe DW, Mottes M, Barisic I, Anticevic D, Mirandola S, Gomez Lira M, Kalajzic I, Kusec V, Glorieux FH (2001) Osteogenesis imperfecta at the beginning of bone and joint decade. Croat Med J 4: 393-415.
23. Prockop DJ, Colige A, Helminen H, Khillan JS, Pereira R, Vandenberg P (1993) Mutations in type I procollagen that cause osteogenesis imperfecta: effects of the mutations on the assembly of collagen into fibrils, the basis of phenotypic variations, and potential antisense therapies. J Bone Miner Res 8 Suppl 2: S489-S492.
24. Prosser J (1993) Detecting single-base mutations. Trends Biotechnol 11: 238-246.
25. Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110: 1293-1299.
26. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003a) Osteogenesis imperfecta types I, III and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88: 986-992.
27. Rauch F, Plotkin H, Zeitlin L, Glorieux FH (2003b) Bone mass, size and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy. J Bone Miner Res 18: 610-614.
28. Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16: 101-116.
29. Srivastava T, Alon US (1999) Bisphosphonates: from grandparents to grandchildren. Clin Pediatr (Phila) 38: 687-702.
30. Wallis GA, Sykes B, Byers PH, Mathew CG, Viljoen D, Beighton P (1993) Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible. J Med Genet 30: 492-496.
31. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH (2002) Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31: 12-18.
32. Zeitlin L, Fassier F, Glorieux FH (2003a) Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 12: 77-87.
33. Zeitlin L, Rauch F, Plotkin H, Glorieux FH (2003b) Height and weight development during long-term therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III and IV. Pediatrics 111: 1032-1036.
34. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tatò L (2003) Intravenousneridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18: 126-130.